Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02467400 · ClinicalTrials.gov registry record · Early Phase 1
Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 165
- Enrollment target
NCT02467400: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT02467400 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 165 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02467400, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 165 participants
- Enrollment target
Study Summary
This study is designed to answer the question as to whether the sympathetic nervous system is an important determinant of bone metabolism in humans.
Interventions
- DRUG placebo
- DRUG Atenolol
- DRUG Propranolol
- DRUG Nebivolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2015-07-01 |
| Est. Completion | 2018-04-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02467400
The ClinicalTrials.gov registry entry for NCT02467400 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT02467400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02467400 about?
NCT02467400 is a clinical study titled "Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism". This study is designed to answer the question as to whether the sympathetic nervous system is an important determinant of bone metabolism in humans.
What is the current status of trial NCT02467400?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 165 participants. The study started on 2015-07-01. Estimated completion is 2018-04-01.
What interventions are being tested in trial NCT02467400?
The interventions under investigation include: placebo (DRUG), Atenolol (DRUG), Propranolol (DRUG), Nebivolol (DRUG).
Who is sponsoring clinical trial NCT02467400?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.